Procarbazine and Temozolomide

The combination of procarbazine and temozolomide represents a dual alkylating agent approach used primarily in the treatment of gliomas. This combination therapy has been studied as a strategy to enhance efficacy, particularly in cases where temozolomide monotherapy has failed. ## Pharmacology Temozolomide (TMZ) is an oral alkylating agent that crosses the blood-brain barrier effectively. It functions as a prodrug that spontaneously hydrolyzes at physiological pH to form its active metabolite MTIC (5-(3-methyltriazen-1-yl) imidazole-4-carboxamide), which then releases a highly reactive methyl diazonium cation[4][6]. This methylating agent primarily targets DNA at the N-7 and O-6 positions of guanine and the N-3 position of adenine[8]. The O-6 methylation of guanine is particularly critical for TMZ's cytotoxicity, as it leads to DNA mismatch repair attempts that ultimately trigger cell cycle arrest and apoptosis[8]. Procarbazine (PCB) is another alkylating agent that has been used in glioma treatment for many years. It works by inhibiting protein, RNA, and DNA synthesis[9]. When combined with temozolomide, procarbazine appears to enhance the alkylating effect, potentially overcoming resistance mechanisms. ## Clinical Applications The combination of procarbazine and temozolomide has been studied in several clinical settings: 1. **Recurrent Gliomas**: The combination has shown modest activity in patients with TMZ-exposed gliomas who have experienced disease progression[5]. In one retrospective study, patients received procarbazine (100-150 mg/m²/day) and temozolomide (150-200 mg/m²/day) on days 1-5 of a 28-day cycle after failing previous treatments[5]. 2. **Phase I Studies**: Research has evaluated the safety and efficacy of combining these agents. One phase I study administered TMZ alone for the first course, followed by TMZ with escalating doses of PCB (50-125 mg/m² on days 1-5) in subsequent courses[1]. The combination of TMZ 200 mg/m² and PCB 100 mg/m² was well tolerated and demonstrated antitumor activity[1]. ## Safety Profile The combination therapy is generally well tolerated with few grade 3 or 4 toxicities at recommended doses[1][5]. However, higher doses (PCB 125 mg/m²) have been associated with increased thrombocytopenia and lethargy[1]. One reported adverse event is procarbazine hypersensitivity, which may necessitate treatment discontinuation[5]. ## Resistance Mechanisms The efficacy of this combination may be influenced by several factors: 1. **MGMT Expression**: O-6-methylguanine-DNA methyltransferase (MGMT) can remove the methyl groups added by TMZ, reducing its effectiveness[6][8]. 2. **Mismatch Repair Deficiency**: Defects in the mismatch repair pathway can lead to resistance against both TMZ and procarbazine[7]. This combination represents an important treatment option for patients with malignant gliomas, particularly those who have failed temozolomide monotherapy.